Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;11(2):106-108.
doi: 10.1111/cts.12513. Epub 2017 Nov 28.

Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources

Mara L Becker  1   2 , Ryan S Funk  1   3
Affiliations

Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources

Mara L Becker et al. Clin Transl Sci. 2018 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of factors impacting response to pharmacotherapy. Major factors contributing to the observed variation in drug response among patients includes: heterogeneity in disease, variation in the disposition of the therapeutic agent (i.e., pharmacokinetic variation), and variation in the biochemical and physiological response to the drug (i.e., pharmacodynamic variation).
Figure 2
Figure 2
Schematic of intracellular pharmacokinetics and pharmacodynamics of methotrexate (MTX). Following transporter‐mediated uptake, MTX is reversibly metabolized to form a series of polyglutamated metabolites (MTX‐Glun). MTX inhibits the enzymatic conversion of folic acid (FA) to dihydrofolate (DHF), and DHF to tetrahydrofolate (THF), resulting in the depletion of cellular methylene‐THF (CH2THF), methenyl‐THF (CH=THF), and 5‐methyl‐THF (5mTHF). Depletion of the reduced cellular folate pool by MTX and inhibition of folate‐dependent enzymes by MTX‐Glun results in inhibition of purine, pyrimidine, and methionine biosynthesis.
See this image and copyright information in PMC

References

    1. Russo, R.A. & Katsicas, M.M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti‐tumor necrosis factor agents. J. Rheumatol. 36, 1078–1082 (2009). - PubMed
    1. de Benedetti, F. et al Correlation of serum interleukin‐6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34, 1158–1163 (1991). - PubMed
    1. Pascual, V. et al Role of interleukin‐1 (IL‐1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL‐1 blockade. J. Exp. Med. 201, 1479–1486 (2005). - PMC - PubMed
    1. Barnes, M.G. et al Subtype‐specific peripheral blood gene expression profiles in recent‐onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2102–2112 (2009). - PMC - PubMed
    1. Becker, M.L. et al The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 63, 276–285 (2011). - PubMed

MeSH terms

Substances

LinkOut - more resources